The impact of acute rejection on the development of intimal hyperplasia associated with chronic rejection
Hullett, D.A.; Geraghty, J.G.; Stoltenberg, R.L.; Sollinger, H.W.
Transplantation 62(12): 1842-1846
1996
ISSN/ISBN: 0041-1337 PMID: 8990374 Document Number: 463956
The rat aortic model of chronic rejection was used to study the effect of acute rejection on the development of intimal hyperplasia (IH). Two model systems were studied. In the first, continuous monotherapy with mycophenolate mofetil (MM) (40 mg/d times 14 d followed by 30 mg/kg/d) was initiated 2 or 4 weeks posttransplant. Digital computer image analysis was used to quantify IH. While the development of IH was delayed, it was not prevented. In allografts where NM treatment was delayed for 2 wk, a 35.5% reduction in the amount of IH was observed. Delaying drug treatment for 4 wk resulted in a 42.2% reduction of IH. In contrast, continuous therapy from the time of transplant resulted in a 76.3% reduction in the amount of IH in comparison with untreated allograft controls. To further define the role of acute rejection in the development of IH, aortic allografts, ACI or (ACI times Lewis)F-1 (F-1), were orthotopically transplanted to Lewis recipients and then retransplanted to donor strain secondary recipients after 2 or 4 wk. Grafts were harvested at 12 weeks posttransplant. When the retransplant was performed at 2 wk, intimal hyperplasia was decreased by 55.9% in ACI and by 66.7% in F-1 allografts in comparison to conventional (ACI fwdarw Lewis) allograft controls. When retransplantation was delayed until 4 wk, IH was not decreased in ACI allografts (105.9%) and was only marginally decreased in F-1 allografts (26.2%). Syngeneic control F-1 grafts (F-1 fwdarw F-1 fwdarw F-1) did not develop significant IH at 12 or 20 wk when retransplanted at 2 wk (10% and 12%, respectively) or when retransplanted at 4 wk and harvested at 12 wk (18.6%). A common feature of IH is the development of medial acellularity. Unlike conventional allograft recipients (ACI fwdarw Lewis; no retransplantation), F-1 retransplanted grafts did not develop significant medial myocyte dropout. In contrast, delayed NM immunosuppressive therapy or retransplantation of ACI allografts at 4 weeks to ACI secondary recipients resulted in significant loss of medial myocytes. Our results show that acute rejection, which occurs during the first 4 wk posttransplant, is sufficient to mediate the development of IH associated with CR. However the lack of a continued allogenic environment slows the process.